## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Review Proposal Project**

# NICE Technology Appraisal No. 216; Bendamustine for the treatment of chronic lymphocytic leukaemia

## Provisional matrix of consultees and commentators

| Consultees                            | Commentators (no right to submit or                                                |
|---------------------------------------|------------------------------------------------------------------------------------|
| Manufacturara/anancara                | appeal)                                                                            |
| Manufacturers/sponsors                | <ul><li>General</li><li>Allied Health Professionals Federation</li></ul>           |
| Napp Pharmaceuticals                  |                                                                                    |
| Patient/carer groups                  | <ul> <li>Board of Community Health Councils in Wales</li> </ul>                    |
| Action for Children                   | British National Formulary                                                         |
| Action for Sick children              |                                                                                    |
| Afiya Trust                           | <ul><li>Care Quality Commission</li><li>Commissioning Support Appraisals</li></ul> |
| African Caribbean Leukaemia Trust     | Service                                                                            |
| Anthony Nolan                         | Department of Health, Social Services                                              |
| Aplastic Anaemia Trust                | and Public Safety for Northern Ireland                                             |
| Black Health Agency                   | Healthcare Improvement Scotland                                                    |
| Cancer Black Care                     | Medicines and Healthcare Products                                                  |
| Cancer Equality                       | Regulatory Agency                                                                  |
| Cancer52                              | <ul> <li>National Association of Primary Care</li> </ul>                           |
| Childhood Cancer Parents Alliance     | National Pharmacy Association                                                      |
| Children with Cancer                  | NHS Alliance                                                                       |
| Chronic Lymphocytic Leukaemia         | NHS Commercial Medicines Unit                                                      |
| Support Association                   | NHS Confederation                                                                  |
| Chronic Myeloid Leukaemia Support     | Scottish Medicines Consortium                                                      |
| Group                                 |                                                                                    |
| CLIC Sargent                          | Comparator manufacturers                                                           |
| Equalities National Council           | AAH Pharmaceuticals                                                                |
| Helen Rollason Cancer Charity         | (cyclophosphamide, fludarabine)                                                    |
| Help Adolescents with Cancer          | Actavis (fludarabine)                                                              |
| Independent Cancer Patients Voice     | Aspen (chlorambucil)                                                               |
| Leukaemia Cancer Society              | Baxter Healthcare (cyclophosphamide)                                               |
| Leukaemia CARE                        | Hospira (fludarabine)                                                              |
| Lymphoma Association                  | Pfizer (cyclophosphamide)                                                          |
| Macmillan Cancer Support              | Roche Products (rituximab)                                                         |
| Maggie's Centres                      | Sanofi (fludarabine)                                                               |
| Marie Curie Cancer Care               | Teva (fludarabine)                                                                 |
| Muslim Council of Britain             | Wockhardt (fludarabine)                                                            |
| Muslim Health Network                 | ,                                                                                  |
| National Children's Bureau            |                                                                                    |
| Rarer Cancers Foundation              | Relevant research groups                                                           |
| South Asian Health Foundation         | Cochrane Haematological Malignancies                                               |
| 23dil / loldil   lodili   odiladiloli | Group                                                                              |

Review of NICE Technology Appraisal No. 216; Bendamustine for the treatment of chronic lymphocytic leukaemia

Issue date: December 2013 Page 1 of 2

- Specialised Healthcare Alliance
- Teenage Cancer Trust
- Tenovus
- United Kingdom Chronic Lymphocytic Leukaemia Forum
- WellChild

#### Professional groups

- Association of Cancer Physicians
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Society for Haematology
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Health Forum
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

#### Others

- Department of Health
- NHS Croydon CCG
- NHS England
- NHS Hounslow CCG
- Welsh Government

- Elimination of Leukaemia Fund
- Health Research Authority
- Institute of Cancer Research
- Leukaemia & Lymphoma Research
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Cancer Programme
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Research Institute for the Care of Older People

#### Assessment Group

- Evidence Review Group tbc
- National Institute for Health Research Health Technology Assessment Programme

#### **Associated Guideline Groups**

 National Collaborating Centre for Cancer

#### Associated Public Health Groups

- Public Health England
- Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Review of NICE Technology Appraisal No. 216; Bendamustine for the treatment of chronic lymphocytic leukaemia

Issue date: December 2013 Page 2 of 2

## **APPENDIX A**

## PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: December 2013 Page 3 of 2

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

## Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.

Issue date: December 2013 Page 4 of 2